 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
Internal Medicine Chief Resident, Medical Education Department, Ball Memorial Hospital, Muncie, IN
Clinical Pharmacist, Pharmacy Department, Ball Memorial Hospital
Reprints: Garrick P Hubbard MD, Medical Education, Ball Memorial Hospital, 2401 University Ave., Muncie, IN 47303-3499, FAX 765/751-1451, E-mail angieandgary{at}hotmail.com
OBJECTIVE: To report a seizure occurring secondary to meperidine treatment despite normal renal and central nervous system (CNS) function, and to provide a review of meperidine's role in pain management, including its use in pancreatitis and sphincter of Oddi dysfunction.
CASE SUMMARY: A 55-year-old white woman with a history of sphincter of Oddi dysfunction presented to the emergency department with severe abdominal pain. On admission to the hospital, the serum creatinine level was 0.6 mg/dL with slightly elevated aspartate aminotransferase of 56 U/L (normal range 0-31) and alanine aminotransferase of 34 U/L (0-31). The patient received repeated and escalating doses of intravenous meperidine, resulting in a generalized seizure on day 4 of hospitalization. The accumulated meperidine dose was 2125 mg. Buprenorphine was substituted in place of meperidine, and the patient had no further reported complications. She was then transferred to a tertiary-care facility for sphincter of Oddi reevaluation. An objective causality assessment revealed the adverse drug event as probable.
DISCUSSION: Despite alternative opioids, meperidine continues to be used in pain management. Meperidine is different from other opioids because its active metabolite, normeperidine, is neurotoxic. Patients with renal insufficiency, liver failure, or CNS dysfunction are at increased risk for adverse drug reactions related to normeperidine accumulation. Due to normeperidine's extended half-life, however, accumulation of normeperidine can occur in any patient receiving repeated doses of meperidine.
CONCLUSIONS: This case demonstrates the potential hazards that exist when using meperidine in any patient. Meperidine's inherent risks of both undertreating pain and causing adverse drug reactions should prompt clinicians and health organizations to restrict its use in pain management. This restriction should not make exceptions to meperidine's traditional use in pancreatitis or sphincter of Oddi dysfunction.
Key Words: meperidine, narcotics, pain, pancreatitis, seizures, sphincter of Oddi
Published Online, February 20, 2003. www.theannals.com, DOI 10.1345/aph.1C108
This article has been cited by other articles:
|
|
 |
|
  L. L. Raymo, M. Camejo, and J. Fudin Eradicating analgesic use of meperidine in a hospital Am. J. Health Syst. Pharm., June 1, 2007; 64(11): 1148 - 1152. [Full Text] [PDF]
|
|
 |
 |
 |
 |
 |
 |
 |
